Related Experiment Video
Updated: Nov 22, 2025

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Fidaxomicin Use for Clostridium Difficile Infection Probably Decreases the Effect of Coumadin® in Elderly
Samyak Dhruv1, Abhishek Polavarapu2, Vivek Gumaste2
1Internal Medicine, Staten Island University Hospital, Staten Island, USA.
Abstract:
The incidence of Clostridium difficile infection (CDI) has been decreasing in the last decade, though the incidence of community-acquired CDI has remained stable. In an elderly patient on Coumadin®, we report an unexpected decrease in international normalized ratio (INR) during the treatment of second recurrence of CDI treated with fidaxomicin. According to the available information, fidaxomicin does not interfere with warfarin. However, in this case, warfarin effects diminished, and only with increased dosage therapeutic INR was achieved.
Insights
A patient experienced reduced warfarin effectiveness during Clostridium difficile infection (CDI) treatment with fidaxomicin. This unexpected interaction required increased warfarin dosage to maintain therapeutic international normalized ratio (INR).
Area of Science:
- Infectious Diseases
- Pharmacology
- Internal Medicine
Background:
- Clostridium difficile infection (CDI) incidence is declining, but community-acquired cases remain stable.
- Warfarin, an anticoagulant, requires careful monitoring of the international normalized ratio (INR).
- Fidaxomicin is a treatment for recurrent CDI, with no known drug interactions with warfarin.
Observation:
- An elderly patient with recurrent CDI was treated with fidaxomicin.
- During fidaxomicin treatment, the patient exhibited a significant decrease in INR.
- The patient was concurrently taking warfarin (Coumadin®).
Findings:
- Fidaxomicin treatment for recurrent CDI was associated with diminished warfarin efficacy.
- Therapeutic INR levels were only achieved after increasing the warfarin dosage.
- This case suggests a potential drug interaction between fidaxomicin and warfarin, contrary to existing literature.
Implications:
- Clinicians should be aware of a potential interaction between fidaxomicin and warfarin.
- Close INR monitoring is crucial in patients receiving both fidaxomicin and warfarin.
- Further research is needed to elucidate the mechanism of this interaction and its clinical significance.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drug Dosing: Geriatric Patients
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

